Association of Acute Cerebellar Ataxia and Human Papilloma Virus Vaccination: A Case Report
22 August 2012
02 January 2013
01 February 2013 (online)
Introduction We report the case of a patient who developed symptoms of acute cerebellar ataxia (ACA) after administration of the human papilloma virus (HPV)-16/18 vaccine.
Patient and Method This patient developed symptoms of ACA, including nausea, vertigo, severe limb and truncal ataxia, and bilateral spontaneous continuous horizontal nystagmus with irregular rhythm, 12 days after administration of the HPV-16/18 AS04-adjuvanted cervical cancer vaccine. After this, the patient received methylprednisolone pulse and intravenous immunoglobulin (IVIG) therapies as well as immunoadsorption plasmapheresis.
Results Severe ACA symptoms did not improve after methylprednisolone pulse and IVIG therapies, but the patient recovered completely after immunoadsorption plasmapheresis.
Conclusion This temporal association strongly suggests that ACA was induced by the vaccination.
- 1 Connolly AM, Dodson WE, Prensky AL, Rust RS. Course and outcome of acute cerebellar ataxia. Ann Neurol 1994; 35 (6) 673-679
- 2 Sunaga Y, Hikima A, Ostuka T, Morikawa A. Acute cerebellar ataxia with abnormal MRI lesions after varicella vaccination. Pediatr Neurol 1995; 13 (4) 340-342
- 3 Deisenhammer F, Pohl P, Bösch S, Schmidauer C. Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine. Acta Neurol Scand 1994; 89 (6) 462-463
- 4 Souayah N, Michas-Martin PA, Nasar A , et al. Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011; 29 (5) 886-889
- 5 Nussinovitch M, Prais D, Volovitz B, Shapiro R, Amir J. Post-infectious acute cerebellar ataxia in children. Clin Pediatr (Phila) 2003; 42 (7) 581-584
- 6 Harper DM, Franco EL, Wheeler C , et al; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364 (9447) 1757-1765
- 7 Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 2009; 8 (1) 65-76
- 8 Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (Suppl. 01) S16-S24
- 9 Ribassin-Majed L, Lounes R, Clémençon S. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies. PLoS ONE 2012; 7 (3) e32251
- 10 Marn Pernat A, Buturović-Ponikvar J, Svigelj V, Ponikvar R. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 2009; 13 (4) 310-313